| Withdrawn | (TAA)-Specific Cytotoxic T-Lymphocytes to Pediatric Patients With Lymphomas (pediTACTAL). NCT05134740 | Baylor College of Medicine | Phase 1 |
| Recruiting | A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NH NCT04496349 | Ascentage Pharma Group Inc. | Phase 2 |
| Recruiting | Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) NCT04728893 | Merck Sharp & Dohme LLC | Phase 2 |
| Active Not Recruiting | To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Part NCT04661007 | Incyte Biosciences Japan GK | Phase 1 / Phase 2 |
| Terminated | Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL NCT04240704 | Novartis Pharmaceuticals | Phase 1 |
| Completed | Resiliency in Older Adults Undergoing Bone Marrow Transplant NCT04188678 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | — |
| Terminated | Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractor NCT03465540 | Amgen | Phase 1 |
| Active Not Recruiting | An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With R NCT03533283 | Hoffmann-La Roche | Phase 1 / Phase 2 |
| Completed | A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer NCT02391480 | AbbVie | Phase 1 |
| Completed | Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies NCT02328014 | Acerta Pharma BV | Phase 1 / Phase 2 |
| Terminated | Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lym NCT02110563 | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | Phase 1 |
| Completed | 3rd Party LMP1/2-Specific Cytotoxic T Lymphocytes for EBV-Associated Lymphoma NCT02057445 | New York Medical College | Phase 1 |
| Completed | Use of Hyperbaric Oxygen Therapy to Improve Umbilical Cord Blood Stem Cell Homing and Subsequent Engraftment NCT02099266 | University of Kansas Medical Center | N/A |
| Terminated | Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies NCT01744912 | TG Therapeutics, Inc. | Phase 1 |
| Completed | Study to Evaluate the Safety and Tolerability of Tirabrutinib (ONO/GS-4059) Given as Monotherapy in Participan NCT01659255 | Gilead Sciences | Phase 1 |
| Completed | Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lym NCT01647971 | TG Therapeutics, Inc. | Phase 1 / Phase 2 |
| Terminated | Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor NCT01598025 | Memorial Sloan Kettering Cancer Center | N/A |
| Completed | Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning NCT01572662 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell NCT01500161 | Texas Oncology Cancer Center | Phase 2 |
| Terminated | Relapsed Malignant Blood Cancer After Allogeneic Hematopoietic Stem Cell Transplantation NCT01326728 | National Cancer Institute (NCI) | — |
| Completed | A Study of Escalating Doses of Polatuzumab Vedotin in Participants With Relapsed or Refractory B-Cell Non-Hodg NCT01290549 | Genentech, Inc. | Phase 1 |
| Completed | Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin Lymphoma NCT01281917 | University of Wisconsin, Madison | Phase 2 |
| Terminated | TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation NCT01300611 | Tarix Pharmaceuticals | Phase 1 |
| Unknown | Study of the Best Timing for Plerixafor in Autologous Hematopoietic Stem Cell Collection NCT01042717 | Shi, Patricia, M.D. | N/A |
| Completed | Intensity Modulated Total Marrow Irradiation (IM-TMI) for Advanced Hematologic Malignancies NCT00988013 | University of Illinois at Chicago | N/A |
| Terminated | Pilot Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Matched Unrelated Double Cord Bloo NCT00973804 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Study of Plerixafor for Rescue of Poor Mobilizers in Autologous Stem Cell Transplant NCT00901225 | Duke University | Phase 2 |
| Completed | A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies NCT00807677 | Millennium Pharmaceuticals, Inc. | Phase 1 |
| Terminated | Oncaspar/Doxil/Decadron in Patients With Refractory Lymphoid Malignancies NCT00837200 | Milton S. Hershey Medical Center | Phase 2 |
| Completed | Evaluate Rituximab in Obtaining PCR (Polymerase Chain Reaction) Negative Leukapheresis Product in Patients Wit NCT00856245 | University of Kansas Medical Center | Phase 2 |
| Terminated | Safety of SGI-1776, A PIM Kinase Inhibitor in Refractory Prostate Cancer and Relapsed/Refractory Non Hodgkin's NCT00848601 | Astex Pharmaceuticals, Inc. | Phase 1 |
| Completed | Brown Fat Activity and White Fat Accumulation NCT01517581 | Children's Hospital Los Angeles | — |
| Completed | Blood Samples to Evaluate Biomarkers of Donor Chimerism NCT00764829 | Fred Hutchinson Cancer Center | — |
| Unknown | Zevalin With Non Myeloablative Allogeneic Stem Cell Transplantation in Patients With Non Hodgkin Lymphoma NCT00807196 | Maisonneuve-Rosemont Hospital | Phase 1 / Phase 2 |
| Completed | Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematolo NCT00739141 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients NCT00726934 | Indiana University | N/A |
| Completed | A Bioequivalence Study of Vinorelbine Tartrate Injectable Emulsion in Patients With Advanced Cancer. NCT00432562 | Mast Therapeutics, Inc. | Phase 1 |
| Completed | Aurora Kinase Inhibitor AT9283 in Treating Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin's NCT00443976 | NCIC Clinical Trials Group | Phase 1 |
| Completed | Study of Vinorelbine Liposomes Injection for Advanced Solid Tumors, Non-Hodgkin's Lymphoma or Hodgkin's Diseas NCT00364676 | Spectrum Pharmaceuticals, Inc | Phase 1 |
| Completed | Compassionate Use of Erwinase For Pediatric Patients With Acute Lymphoblastic Leukemia Or Non Hodgkins Lymphom NCT00693602 | St. Jude Children's Research Hospital | Phase 1 |
| Completed | Safety And Efficacy Of Lenalidomide In Patients With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma NCT00179660 | Celgene Corporation | Phase 2 |
| Terminated | Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma NCT00126191 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma NCT00179673 | Celgene | Phase 2 |
| Completed | Irinotecan, Vincristine, and Dexamethasone In Children With Relapsed And/Or Refractory Hematologic Malignancie NCT00718757 | St. Jude Children's Research Hospital | Phase 1 |
| Enrolling By Invitation | Biology Studies of Hematologic Cancers NCT00923442 | National Cancer Institute (NCI) | — |
| Completed | Ifosfamide/Carboplatin/Etoposide/Rituxan Followed by Zevalin in Relapsed/Refractory Intermediate Grade B-Cell NCT00193505 | SCRI Development Innovations, LLC | Phase 2 |
| Completed | Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's NCT00193479 | SCRI Development Innovations, LLC | Phase 2 |
| Terminated | Study of 90Y-hLL2 to Treat Non-Hodgkin's Lymphoma NCT00054834 | Gilead Sciences | Phase 1 |
| Terminated | Phase I/II Study of CAMPATH in Patients With Relapsing or Refractory Non-Hodgkin's Lymphoma NCT00051701 | Genzyme, a Sanofi Company | Phase 1 / Phase 2 |
| Completed | Safety Study of NHL With 90Y-hLL2 IgG NCT00421395 | Gilead Sciences | Phase 1 / Phase 2 |
| Completed | Rituximab and Chemotherapy Followed by Ibritumomab Tiuxetan as Treatment for Low Grade Follicular Non-Hodgkin' NCT00193440 | SCRI Development Innovations, LLC | Phase 2 |
| Completed | Rituximab and Fludarabine Followed by CAMPATH-1H in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma NCT00193466 | SCRI Development Innovations, LLC | Phase 2 |
| Completed | CHOP/Rituximab Followed by Maintenance PEG Intron in Treatment of Indolent/Follicular Non-Hodgkin's Lymphoma NCT00574730 | University of Nebraska | N/A |
| Completed | Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant NCT00571662 | University of Nebraska | Phase 2 |
| Completed | T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts NCT00368355 | Baylor College of Medicine | Phase 2 |
| Unknown | Study of the BiovaxId Tumor Derived Idiotype Vaccine in Patients With Follicular Lymphoma NCT00091676 | Biovest International | Phase 3 |
| Terminated | Antineoplaston Therapy in Treating Patients With High-Grade Stage II - Stage IV Non-Hodgkin's Lymphoma NCT00003501 | Burzynski Research Institute | Phase 2 |
| Terminated | Antineoplaston Therapy in Treating Patients With Intermediate-Grade Stage II - IV Non-Hodgkin's Lymphoma NCT00003500 | Burzynski Research Institute | Phase 2 |
| Terminated | Giving Gene Marked EBV Specific T-Cells to Patients Receiving a BMT for Relapsed EBV-Positive Hodgkin Disease NCT00058773 | Baylor College of Medicine | Phase 1 |
| Completed | Treatment and Natural History Study of Lymphomatoid Granulomatosis NCT00001379 | National Cancer Institute (NCI) | Phase 2 |
| Completed | A Retrospective Review of Gemcitabine, Methylprednisolone Cisplatin (GEM-P) With or Without Rituximab in Patie NCT00301301 | Royal Marsden NHS Foundation Trust | — |
| Completed | A Retrospective Study of Toxicity and Outcome of High Dose Chemotherapy With Autologous Stem Cell Transplant i NCT00301288 | Royal Marsden NHS Foundation Trust | — |